Glaukos Corporation (NYSE:GKOS), a company specializing in the development and commercialization of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, has reported an insider sale according to a recent SEC filing.
Joseph Gilliam, President & COO of Glaukos Corp (NYSE:GKOS), executed a sale of 25,000 shares in the company on December 21, 2023, according to a SEC Filing.